HomeAI · summaries
Storia in 2 fonti
Abemaciclib may be new standard for ‘challenging’ sarcoma subtype
CHICAGO — Abemaciclib significantly prolonged PFS compared with placebo for patients with advanced dedifferentiated liposarcoma, according to findings presented during ASCO Annual Meeting’s plenary session.Results of the randomized phase 3 SARC041 trial — the first-ever positive phase 3 trial in dedifferentiated sarcoma — showed a trend toward longer OS with the agent,
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
medpagetoday.com
Abemaciclib Poised to Be New Standard of Care in Aggressive Liposarcoma
Treatment with CDK4/6 inhibitor led to nearly 10-month median PFS in placebo-controlled SARC041
- ·
healio.com
Abemaciclib may be new standard for ‘challenging’ sarcoma subtype
CHICAGO — Abemaciclib significantly prolonged PFS compared with placebo for patients with advanced dedifferentiated liposarcoma, according to findings presented during ASCO Annual…